- Home
- UBX vs KUKE Comparison
UBX vs KUKE Comparison
Compare UBX & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- KUKE
- Stock Information
- Founded
- UBX 2009
- KUKE 2002
- Country
- UBX United States
- KUKE China
- Employees
- UBX N/A
- KUKE N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- KUKE Other Consumer Services
- Sector
- UBX Health Care
- KUKE Real Estate
- Exchange
- UBX Nasdaq
- KUKE Nasdaq
- Market Cap
- UBX 24.6M
- KUKE 21.2M
- IPO Year
- UBX 2018
- KUKE 2021
- Fundamental
- Price
- UBX $1.26
- KUKE $0.40
- Analyst Decision
- UBX Strong Buy
- KUKE
- Analyst Count
- UBX 3
- KUKE 0
- Target Price
- UBX $9.00
- KUKE N/A
- AVG Volume (30 Days)
- UBX 70.7K
- KUKE 1.2M
- Earning Date
- UBX 11-04-2024
- KUKE 12-26-2024
- Dividend Yield
- UBX N/A
- KUKE N/A
- EPS Growth
- UBX N/A
- KUKE N/A
- EPS
- UBX N/A
- KUKE N/A
- Revenue
- UBX N/A
- KUKE $14,784,158.00
- Revenue This Year
- UBX N/A
- KUKE N/A
- Revenue Next Year
- UBX N/A
- KUKE N/A
- P/E Ratio
- UBX N/A
- KUKE N/A
- Revenue Growth
- UBX N/A
- KUKE 10.48
- 52 Week Low
- UBX $1.11
- KUKE $0.34
- 52 Week High
- UBX $2.26
- KUKE $4.07
- Technical
- Relative Strength Index (RSI)
- UBX 47.73
- KUKE 38.35
- Support Level
- UBX $1.11
- KUKE $0.38
- Resistance Level
- UBX $1.37
- KUKE $0.54
- Average True Range (ATR)
- UBX 0.08
- KUKE 0.15
- MACD
- UBX 0.00
- KUKE -0.01
- Stochastic Oscillator
- UBX 69.49
- KUKE 10.61
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.